37 / 62
a
Select AEs are those with potential immunologic etiology that require frequent monitoring/intervention; includes events reported between first dose and 30 days after last dose of study drug
Related Select AEs
Select TRAE,
a
n (%)
Nivolumab
(n = 282)
Chemotherapy
(n = 265)
Any grade
Grade 3–4
Any grade
Grade 3–4
Endocrine
33 (12)
2 (1)
0
0
Skin
32 (11)
1 (0.4)
3 (1)
1 (0.4)
Gastrointestinal
20 (7)
3 (1)
24 (9)
4 (2)
Hepatic
13 (5)
7 (2)
15 (6)
1 (0.4)
Pulmonary
13 (5)
4 (1)
1 (0.4)
0
Hypersensitivity/infusion reaction
12 (4)
0
16 (6)
2 (1)
Renal
6 (2)
1 (0.4)
5 (2)
0
37